• Go to navigation
  • Go to content

Syn2bio

  • Syn2bio
  • SYN2 Cardiotracer
    • Medical context
    • What is SYN2
    • SYN2’s advantages
    • Research history
  • Investor relations
    • Shares on the WSE
    • Current reports
    • Corporate Governance
    • General Meetings
    • Division of Synektik SA
    • Public offering
    • Investor calendar
    • IR contact
  • News
  • Contact
  • pl

News

  • Homepage
  • >ESPI
  • All
  • Corporate news
  • Investor relations

ESPI

2026-05-20

List of shareholders holding at least 5% of the total number of votes at the Extraordinary Shareholder Meeting on 19 May 2026

2026-05-19

Resolutions adopted by the Extraordinary Shareholder Meeting of Syn2bio SA on 19 May 2026

2026-04-23

Convening an Extraordinary Shareholder Meeting

2026-04-22

Execution of the final treasury (founders’) share purchase agreement by the Company

2026-04-20

Notification of transactions on the Company’s shares

2026-04-20

Notification of transactions on the Company’s shares

2026-04-13

Estimated value of the amount of financing transferred as part of the Demerger

2026-04-10

Introduction of ordinary series A and B bearer shares to be traded on the Main Market of the Warsaw Stock Exchange

2026-04-09

Receipt of notification pursuant to Article 69 of the Act on Public Offering – change in the status of ownership of the Issuer’s shares

<
  • 1
  • 2
>
  • Syn2bio
  • SYN2 Cardiotracer
  • Investor relations
  • News
Syn2bio SA
ul. J. P. Dziekońskiego 3
00-728 Warszawa

phone: +48 22 327 09 10

e-mail: kontakt@syn2bio.pl

  • Privacy and cookie policy
© 2026 Syn2bio